Browse the evidence

GIP receptor antagonism, when combined with GLP-1 receptor agonism, produces superior weight loss and glycemic control compared to GLP-1 receptor agonism alone.

Current research indicates that combining a GIP receptor antagonist with a GLP-1 agonist (like the investigational drug AMG133) leads to greater weight loss and better blood sugar control than using a GLP-1 agonist alone. This benefit is seen in clinical trials with sustained effects, though the exact mechanism of the GIP part's contribution to weight loss is not fully understood.

Tirzepatide, a dual GLP-1 and GIP agonist, significantly reduces Obstructive Sleep Apnea (OSA) severity and body weight in patients with moderate-to-severe OSA and obesity, marking the first FDA-approved pharmacotherapy for this condition.

If you have moderate-to-severe sleep apnea and obesity, tirzepatide is a new, FDA-approved option. It is a once-weekly injection that helps you lose significant weight (16-17%) and reduces your sleep apnea severity (AHI) by 20-24 events per hour. While it may cause temporary stomach issues, it offers a dual benefit for both your sleep and metabolic health.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE) and cardiovascular death in people with type 2 diabetes and established CVD.

GLP-1 receptor agonists are effective medications that reduce heart attack and stroke risk in people with diabetes or existing heart disease. Access is improving but remains a barrier due to cost.

Tirzepatide produces greater magnitude and faster velocity of weight loss compared to semaglutide in real-world clinical practice.

If you are choosing between Tirzepatide and Semaglutide for weight loss, Tirzepatide is associated with losing more weight (approx 4% more on average) and losing it faster in the first year. This is based on real-world data from over 20,000 patients.

Tirzepatide is associated with a lower prevalence of gastrointestinal and systemic adverse events compared to semaglutide, particularly in high responders.

If you are concerned about side effects like nausea or vomiting, Tirzepatide may be better tolerated than Semaglutide in real-world use, especially if you are a 'high responder' to the drug.

Demographic disparities exist in weight loss response to GLP-1RAs, with White and female patients more likely to be high responders, while Black and Hispanic patients are more likely to be minimal responders.

Be aware that real-world data shows White and female patients are more likely to achieve high weight loss with GLP-1RAs, while Black and Hispanic patients are more likely to have minimal weight loss. This highlights the need for personalized treatment strategies.

Sleeve gastrectomy (SG) induces metabolic changes beyond restriction by reducing ghrelin and increasing GLP-1 and GIP, which stimulates insulin release and delays gastric emptying to improve type 2 diabetes.

If you undergo sleeve gastrectomy, your body's hormone production changes to help control blood sugar and hunger, not just because your stomach is smaller. This metabolic shift is a key reason why type 2 diabetes often improves after this specific surgery.

GLP-1 and GIP receptor agonists reduce the composite incidence of death due to cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke in patients with overweight or obesity.

If you have overweight or obesity, GLP-1 and GIP receptor agonists like semaglutide can reduce your risk of cardiovascular events, including death, heart attack, and stroke.

Semaglutide (2.4 mg weekly) produces significant weight loss (mean -14.9%) in non-diabetic adults with obesity, but this efficacy is accompanied by a high incidence of mild-to-moderate gastrointestinal adverse events (nausea, vomiting, diarrhea) that often lead to treatment discontinuation.

Semaglutide 2.4mg weekly is highly effective for weight loss in non-diabetics, but expect significant gastrointestinal side effects like nausea and vomiting, especially during the first 16 weeks. These side effects are usually mild-to-moderate and transient, but they are the main reason people stop treatment. Medical supervision is crucial to manage these risks and monitor for rare but serious issues like pancreatitis.

A domestic synthetic semaglutide product (Quincenta) demonstrates bioequivalence, comparable pharmacokinetics, and a similar safety/tolerability profile to the reference originator product (Ozempic) in healthy volunteers.

This study confirms that a specific domestic version of semaglutide (Quincenta) behaves in the body similarly to the brand-name version (Ozempic) when given as a single 0.5 mg dose to healthy people. It had no adverse effects and was not immunogenic. This supports the safety and interchangeability of this specific domestic product with the originator.

Semaglutide (2.4 mg/week) achieves high rates of NASH resolution without worsening fibrosis in patients with obesity.

Semaglutide (Ozempic/Wegovy) is a highly effective treatment for resolving NASH. In trials, 59% of patients achieved resolution of the disease without worsening liver scarring, compared to only 17% on placebo. It is administered as a weekly injection.

Four months of supervised endurance exercise training significantly reduces circulating leukocyte counts, particularly effector subtypes (CD4+ Teff, NK cells, neutrophils), in patients with metabolic syndrome.

If you have metabolic syndrome, engaging in supervised endurance exercise for 3-4 months can significantly lower your circulating immune cell counts, specifically those linked to inflammation (effector T cells, NK cells, neutrophils). This benefit occurs regardless of whether you choose moderate continuous training or high-intensity intervals, suggesting consistency and duration are key drivers for immune modulation.

A one-week complete cessation from resistance training (detraining) at the midpoint of a 9-week program does not enhance hypertrophy, power, or endurance compared to continuous training, and significantly reduces strength gains.

If your goal is maximizing strength and size, do not take a full week off from training. This study shows that one week of complete rest during a training block blunts strength gains without improving muscle size. If you are fatigued, consider a 'deload' with reduced volume or intensity rather than complete cessation.

Combining multiple receptor pathways (e.g., GLP-1/GIP, GLP-1/Amylin, or GLP-1/Glucagon) produces synergistic and superior weight loss compared to monotherapy, representing a historical inflection point in obesity pharmacotherapy.

Obesity is a chronic biological disease requiring physiological treatment, not just willpower. Modern combination therapies (targeting GLP-1, GIP, Amylin, or Glucagon receptors) are significantly more effective than older drugs or lifestyle changes alone, achieving 15-24% weight loss in trials. While access and cost are current barriers, these medications are designed to be used alongside lifestyle modifications to overcome biological forces promoting weight gain. Consult a provider about whether combination receptor agonists are appropriate for your health profile.

In patients with type 2 diabetes, initiating tirzepatide (a dual GIP/GLP-1 receptor agonist) results in significantly greater reductions in HbA1c and body weight compared to initiating injectable semaglutide (a GLP-1 receptor agonist) over a 12-month period, regardless of prior GLP-1 RA exposure.

If you have Type 2 Diabetes and are starting a GLP-1 based therapy, choosing tirzepatide over semaglutide is likely to result in better blood sugar control and more significant weight loss over the first year. This benefit holds true whether you have never used these drugs before or have tried semaglutide previously. The trade-off is managing the weekly injection schedule and potential side effects, but the metabolic gains are statistically superior.

Retatrutide increases the rate of gastrointestinal adverse events (nausea, vomiting, constipation) and hypersensitivity reactions compared to placebo, but does not significantly increase serious adverse events.

Be aware that retatrutide is more likely to cause nausea, vomiting, and constipation than a placebo. However, these are typically not 'serious' adverse events, and the drug does not appear to increase the risk of serious health complications or death compared to no treatment. Monitor your symptoms and communicate with your doctor.

Combined exercise and pharmacotherapy significantly reduces systolic and diastolic blood pressure and triglycerides compared to exercise alone, but does not significantly improve fasting glucose, HDL, or LDL.

While adding medication to exercise improves blood pressure and triglycerides, it may not significantly improve fasting glucose or cholesterol levels (HDL/LDL) compared to medication alone. Focus on the weight loss and blood pressure benefits.

Sleep curtailment (4 hours/night for 2 nights) in healthy young men significantly decreases leptin levels, increases ghrelin levels, and increases hunger and appetite, particularly for calorie-dense, high-carbohydrate foods.

If you are trying to manage your weight, prioritize getting enough sleep. Restricting sleep to 4 hours for just two nights can significantly increase your hunger and cravings for high-calorie, high-carb foods by altering your hunger hormones. This is not just willpower; it is a biological response to sleep loss.

Consumption of industrial trans fatty acids (iTFA) increases the risk of cardiovascular disease and myocardial infarction through pro-inflammatory actions and atherosclerosis development, whereas ruminant trans fatty acids (rTFA) may possess anti-atherogenic properties.

Be mindful of industrial trans fats found in processed foods, as they are strongly linked to heart disease and inflammation. However, do not fear naturally occurring trans fats in animal products (like those from grass-fed animals) as much, as they may not carry the same risks and might even offer some protection against atherosclerosis.

Consumption of n-3 polyunsaturated fatty acids (PUFAs), specifically EPA and DHA, provides cardioprotection by reducing inflammation, preventing microthrombus formation, and improving survival post-ischemia.

Increase your intake of n-3 PUFAs found in fish and marine animals (EPA and DHA) or plant sources like flaxseed (ALA). These fats help reduce inflammation, prevent blood clots, and protect the heart during stress, unlike diets high in n-6 PUFAs which may increase heart attack risk.

Metformin is the first-line pharmacological treatment for Type 2 Diabetes, reducing HbA1c by ~1.5% and fasting glucose by ~20%, with additional cardiovascular and potential cancer-preventive benefits.

Metformin is the standard first drug for Type 2 Diabetes. It lowers blood sugar by about 1.5% and helps heart health. Common side effects like stomach upset are usually mild and go away. It is safe for kidneys if your eGFR is above 45. If your kidney function drops below 30, you should not take it.

A very low-carbohydrate diet improves metabolic syndrome components (HDL, triglycerides, insulin sensitivity) more effectively than low-fat or low-glycemic index diets during weight-loss maintenance, despite potentially increasing stress hormones (cortisol) and inflammation (CRP).

For long-term health markers like cholesterol and blood sugar, a very low-carbohydrate diet may offer better improvements than low-fat or low-glycemic diets after weight loss. However, monitor your stress levels and inflammation, as this diet may increase cortisol and CRP in some individuals.

Consumption of fructose-rich beverages (sugar-sweetened soda and orange juice) increases the risk of incident gout in women, whereas diet soda does not.

If you are a woman concerned about gout, limit your intake of sugar-sweetened sodas and orange juice. The risk increases significantly with 1-2+ servings per day. Diet sodas do not appear to carry this risk. Focus on reducing fructose-rich beverages rather than just purine-rich foods.

High consumption of fish (more than three times per week) is associated with a significantly reduced risk of metastatic prostate cancer, whereas fish oil supplements show no such protective association.

To potentially lower your risk of developing aggressive, metastatic prostate cancer, aim to eat fish more than three times a week. Focus on fish like salmon, mackerel, sardines, bluefish, and swordfish, as well as canned tuna. Simply taking fish oil supplements does not appear to offer the same protection, suggesting the whole food is key. Note that other seafood like shrimp and lobster did not show this specific benefit.